Skip to main content

Arginine an Enhancer of Gold Nanoparticle Induced Blocking of S-Phase Cell Cycle in HL60

Buy Article:

$105.00 plus tax (Refund Policy)

Gold nanosurface has the potential to act as an anticancer agent. In this report we show that arginine conjugated gold nanoparticles can be cytotoxic to leukemia cells through the perturbation of the cell cycle. Pro-myelotic leukemia cell HL60 that can differentiate to its terminal lineage, can be arrested at the S phase of the cell cycle by such nanoparticles. Importantly, arginine, a non-toxic metabolite, serves as a dose dependent enhancer of gold nanoparticle induced cytotoxicity.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ARGININE; CELL CYCLE BLOCKER; GOLD NANOPARTICLE; HL60; S PHASE

Document Type: Research Article

Publication date: 2011-11-01

More about this publication?
  • ADVANCED SCIENCE LETTERS is an international peer-reviewed journal with a very wide-ranging coverage, consolidates research activities in all areas of (1) Physical Sciences, (2) Biological Sciences, (3) Mathematical Sciences, (4) Engineering, (5) Computer and Information Sciences, and (6) Geosciences to publish original short communications, full research papers and timely brief (mini) reviews with authors photo and biography encompassing the basic and applied research and current developments in educational aspects of these scientific areas.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more